Company
Sunshine Lake Pharma CO LTD
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
1
1 still marketed
Novel approvals
0
Approvals since 2021
1
Originals and new uses
Phase 3 trials
7
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Langlara approved Apr 29, 2026
Drugs in development (5)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- Tegafur-gimeracil-oteracil potassiumS-1, tegafurPhase 38 trials
Ono Pharmaceutical Co., Ltd. · Gastric Cancer, Esophageal Cancer, Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
- HEC585Phase 33 trials
Sunshine Lake Pharma Co., Ltd. · Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF), Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
- ClifutinibHEC73543Phase 32 trials
Sunshine Lake Pharma Co., Ltd. · Leukemia, Acute Myeloid (AML), Acute Myeloid Leukemia, Adult
- LerotinibZ650Phase 31 trial
Sunshine Lake Pharma Co., Ltd. · Esophageal Cancer
- HEC53856Phase 21 trial
Sunshine Lake Pharma Co., Ltd. · Chemotherapy-induced Anemia, Non-Myeloid Malignancy
Recruiting Phase 3 trials
Largest first.
- The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Treatment of Patient With Major Depressive DisorderPivotal-lookingRecruiting
Sunshine Lake Pharma Co., Ltd.Industry
NCT04984512 · 600 participants (planned) · Start Dec 14, 2021 · Primary completion Jul 2027
Drug: Mitizodone Phosphate tablets; Placebo-matching tablets · For: Depressive Disorder, Major
Sites: Dongguan, China
- Confirmatory Clinical Study of HEC585 Tablets in Patients With IPFPivotal-lookingRecruiting
Sunshine Lake Pharma Co., Ltd.Industry
NCT07082842 · 472 participants (planned) · Start Oct 27, 2025 · Primary completion Jan 15, 2031
Drug: HEC585; Placebo and 1 more · For: Idiopathic Pulmonary Fibrosis (IPF)
Sites: Beijing, China
- Study of Larotinib in Unresectable Advanced or Recurrent Esophageal CancerPivotal-lookingRecruiting
Sunshine Lake Pharma Co., Ltd.Industry
NCT04415853 · 416 participants (planned) · Start Jan 21, 2021 · Primary completion Aug 2027
Drug: Lerotinib; Irinotecan/Tegafur · For: Esophageal Cancer
Sites: Beijing, China
- HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AMLPivotal-lookingRecruiting
Sunshine Lake Pharma Co., Ltd.Industry
NCT05586074 · 324 participants (planned) · Start Mar 3, 2023 · Primary completion Nov 30, 2027
Drug: Clifutinib; LoDAC and 4 more · For: Leukemia, Acute Myeloid (AML)
Sites: Hanzhou, China
Marketed drugs (1)
Newest FDA action first.
- Langlara Insulin Glargine-Aldy · 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.